The deal would include an option for expansion to 160 million doses of the mRNA-based vaccine.

Amid speculation it has filed for a generic to Teva’s asthma product Qvar in the US, Aurobindo hopes a healthy product pipeline will help it maintain growth despite pandemic-led challenges. Meanwhile, building on assets acquired from Profectus BioSciences, the firm has thrown its hat in the ring for a COVID-19 vaccine.

Building on assets acquired from Profectus BioSciences, Aurobindo Pharma has thrown its hat in the ring for a COVID-19 vaccine. Amid speculation it has filed for a generic to Teva’s asthma product Qvar in the US, the company hopes a healthy product pipeline will help it maintain growth despite pandemic-led challenges.

Coronavirus-induced stockpiling and advanced prescribing of medicines has resulted in generics companies across the world registering unprecedented growth during the first quarter of 2020. However, many companies predict sales will level off again in the next quarter and beyond. And as demand fluctuates following the COVID-19 outbreak, firms have started taking precautionary measures to avoid supply-chain disruptions.